Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 2/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.87 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.87 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.87 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.87 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.87 |
| ▸ | TSHR | P16473 | 1/20 | 0.87 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.62 |
| ▸ | F7 | P08709 | 3/20 | 0.62 |
| ▸ | F3 | P13726 | 3/20 | 0.62 |
| ▸ | PPARG | P37231 | 3/20 | 0.62 |
| ▸ | OXER1 | Q8TDS5 | 3/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | PPARD | Q03181 | 2/20 | 0.62 |
| ▸ | PPARA | Q07869 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Icosapent Ethyl SCHEMBL119167 | 1.00 | ADORA3 (1.00) | ADORA3NR1I2PTGS2PGRPDE4D | |
| Icosapent Ethyl SCHEMBL28366934 | 1.00 | ADORA3 (1.00) | ADORA3NR1I2PTGS2PGRPDE4D | |
| Icosapent Ethyl SCHEMBL28253974 | 1.00 | ADORA3 (1.00) | ADORA3NR1I2PTGS2PGRPDE4D | |
| Icosapent Ethyl SCHEMBL119168 | 1.00 | ADORA3 (1.00) | ADORA3NR1I2PTGS2PGRPDE4D | |
| Icosapent Ethyl SCHEMBL29356075 | 0.97 | ADORA3 (0.93) | ADORA3NR1I2PTGS2PGRPDE4D | |
| SCHEMBL28628574 | 0.95 | ALDH1A1 (0.97) | ADORA3NR1I2PTGS2PGRPDE4D | |
| SCHEMBL21670446 | 0.95 | ALDH1A1 (0.97) | ADORA3NR1I2PTGS2PGRPDE4D | |
| SCHEMBL21670445 | 0.95 | ALDH1A1 (0.97) | ADORA3NR1I2PTGS2PGRPDE4D | |
| SCHEMBL18924751 | 0.94 | ADORA3 (0.89) | ADORA3NR1I2PTGS2PGRPDE4D | |
| SCHEMBL4814473 | 0.93 | ALDH1A1 (1.00) | ADORA3NR1I2PTGS2PGRPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1655 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3700518-B1 | METHODS OF REDUCING THE RISK OF CARDIOVASCULAR EVENTS IN A SUBJECT WITH A COMPOSITION COMPRISING ICOSAPENT ETHYL | AMARIN PHARMACEUTICALS IE LTD (IE) | 2026-05-13 | — | — | EP | claimed |
| WO-2024254589-A9 | PRODUCTS AND COMPOSITIONS | SIRNAOMICS, INC. (US) | 2025-12-26 | — | — | WO | claimed |
| US-20250382291-A1 | SUBSTITUTED PYRROLO[2,3-b]PYRIDINES FOR SUPPRESSING TOXIC ENDOPLASMIC RETICULUM STRESS | UNIV COLUMBIA (US) | 2025-12-18 | — | — | US | claimed |
| EP-4587573-A2 | PRODUCTS AND COMPOSITIONS | Sirnaomics, Inc. (US) | 2025-07-23 | — | — | EP | claimed |
| US-20250213517-A1 | METHODS OF REDUCING THE RISK OF HEART FAILURE | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2025-07-03 | — | — | US | claimed |
| US-20250177377-A1 | TARGETING PTCHD1 AND NEURONAL CHOLESTEROL TO ENHANCE SAFETY OF OPIOID ANALGESICS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2025-06-05 | — | — | US | claimed |
| US-20250144061-A1 | METHODS OF TREATING MIXED DYSLIPIDEMIA | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2025-05-08 | — | — | US | claimed |
| US-20250090547-A1 | EPA-EE LIPID NANOCOMPOSITE, FORMULATION THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2025-03-20 | — | — | US | claimed |
| WO-2024163497-A9 | PRODUCTS AND COMPOSITIONS | SIRNAOMICS, INC. (US) | 2025-03-06 | — | — | WO | claimed |
| US-12227500-B2 | Substituted pyrrolo[2,3-b]pyridines for suppressing toxic endoplasmic reticulum stress | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-02-18 | — | — | US | claimed |
| US-20220079907-A1 | METHODS OF TREATING MIXED DYSLIPIDEMIA | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2022-03-17 | — | — | US | claimed |
| WO-2021209740-A1 | METHODS INVOLVING NEUTROPHIL ELASTASE INHIBITOR ALVELESTAT FOR TREATING CORONAVIRUS INFECTION | MEREO BIOPHARMA 4 LIMITED (GB) | 2021-10-21 | — | — | WO | claimed |
| CN-107106873-A | ACC inhibitor combined therapies for treating non-alcoholic fatty liver disease | 吉利德阿波罗公司 | 2017-08-29 | — | — | CN | claimed |
| EP-3054940-A1 | COMPOSITIONS AND METHODS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | Mochida Pharmaceutical Co., Ltd. (JP) | 2016-08-17 | — | — | EP | claimed |
| US-20160213639-A1 | COMPOSITIONS AND METHODS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2016-07-28 | — | — | US | claimed |
| EP-2968245-A2 | COMPOSITIONS AND METHODS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | Mochida Pharmaceutical Co., Ltd. (JP) | 2016-01-20 | — | — | EP | claimed |
| WO-2015053379-A1 | COMPOSITIONS AND METHODS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-04-16 | — | — | WO | claimed |
| US-20150051143-A1 | COMPOSITIONS AND METHODS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | MOCHIDA PHARMACEUTICAL CO., LTD (JP) | 2015-02-19 | — | — | US | claimed |
| WO-2014142364-A2 | COMPOSITIONS AND METHODS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2014-09-18 | — | — | WO | claimed |
| WO-2007128801-A1 | COMBINATION OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-11-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250144061-A1 | METHODS OF TREATING MIXED DYSLIPIDEMIA | LIPA, LIPC, PNLIP | ADORA3 1704/4885NR1I2 1184/4885PTGS2 440/4885 |
| US-12227500-B2 | Substituted pyrrolo[2,3-b]pyridines for suppressing toxic endoplasmic reticulum stress | HSPA5, ATP2A1, DNAJC10 | ADORA3 2753/4885NR1I2 2245/4885PTGS2 580/4885 |
| US-20220079907-A1 | METHODS OF TREATING MIXED DYSLIPIDEMIA | LIPA, LIPC, PNLIP | ADORA3 1704/4885NR1I2 1184/4885PTGS2 440/4885 |
| US-20250382291-A1 | SUBSTITUTED PYRROLO[2,3-b]PYRIDINES FOR SUPPRESSING TOXIC ENDOPLASMIC RETICULUM STRESS | HSPA5, ATP2A1, DNAJC10 | ADORA3 2753/4885NR1I2 2245/4885PTGS2 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.